<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737369</url>
  </required_header>
  <id_info>
    <org_study_id>MMNM01</org_study_id>
    <nct_id>NCT04737369</nct_id>
  </id_info>
  <brief_title>Multimodal Neuromonitoring</brief_title>
  <acronym>MMNM</acronym>
  <official_title>Multimodal Neuromonitoring: an Explorative Study in Neurocritical Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karl Landsteiner Institute for Clinical Epilepsy Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theoretical Framework &amp; Background&#xD;
&#xD;
      Cortical spreading depressions (CSD) and seizures, are crucial in the development of delayed&#xD;
      cerebral ischemia and poor functional outcome in patients suffering from acute brain injuries&#xD;
      such as subarachnoid hemorrhage. Multimodal neuromonitoring (MMNM) provides the unique&#xD;
      possibility in the sedated and mechanically ventilated patients to record these&#xD;
      electrophysiological phenomena and relate them to measures of cerebral ischemia and&#xD;
      malperfusion. MMNM combines invasive (e.g. electrocorticography, cerebral microdialysis,&#xD;
      brain tissue oxygenation) and noninvasive (e.g. neuroimaging, continuous EEG) techniques.&#xD;
      Additionally, cerebral microdialysis can measure the unbound extracellular drug&#xD;
      concentrations of sedatives, which potentially inhibit CSD and seizures in various degrees,&#xD;
      beyond the blood-brain barrier without further interventions.&#xD;
&#xD;
      Hypotheses&#xD;
&#xD;
        1. Online multimodal neuromonitoring can accurately detect changes in neuronal metabolic&#xD;
           demand and pathological neuronal bioelectrical changes in highly vulnerable brain&#xD;
           tissue.&#xD;
&#xD;
        2. Online multimodal neuromonitoring can accurately detect the impact of pathological&#xD;
           neuronal bioelectrical changes on metabolic demand in highly vulnerable brain tissue.&#xD;
&#xD;
        3. The occurrence and duration of pathological neuronal bioelectrical changes are dependent&#xD;
           on sedatives and antiepileptic drug concentrations&#xD;
&#xD;
        4. The occurrence and duration of pathological neuronal bioelectrical changes have a&#xD;
           negative impact on functional and neurological long-term patient outcome.&#xD;
&#xD;
        5. Simultaneous invasive and non-invasive multimodal neuromonitoring can identify a clear&#xD;
           relationship of both methods regarding pathological neuronal bioelectrical changes and&#xD;
           metabolic brain status.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Systematic analysis of MMNM measurements following standardized criteria and correlation of&#xD;
      electrophysiological phenomena with cerebral metabolic changes in all included patients. In a&#xD;
      second step neuroimaging, cerebral extracellular sedative drug concentrations and&#xD;
      neurological functional outcome, will be correlated with both electrophysiologic and&#xD;
      metabolic changes. Due to numerous high-resolution parameters, machine learning algorithms&#xD;
      will be used to correlate comprehensive data on group and individual levels following a&#xD;
      holistic approach.&#xD;
&#xD;
      Level of originality&#xD;
&#xD;
      Extensive, cutting edge diagnostic methods are used to get a better insight into the&#xD;
      pathophysiology of electrophysiological and metabolic changes during the development of&#xD;
      secondary brain damage. Due to the immense amount of high-resolution data, a&#xD;
      computer-assisted evaluation will be applied to identify relationships in the development of&#xD;
      secondary brain injury. For the first time systematic testing of several drug concentrations&#xD;
      beyond the blood-brain barrier will be performed. With these combined methods, we will be&#xD;
      able to develop new cerebroprotective treatment concepts on an individual basis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Count of SD during electrocorticography</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Count of cortical spreading depolarization (SD) during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily pattern duration of CSD during electrocorticography</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of cortical spreading depression (CSD) per hour during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily pattern duration of NCSE during electrocorticography</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of nonconvulsive status epilepticus (NCSE) per hour during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily pattern duration of RPPIIC during electrocorticography</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of rhythmic or periodic EEG patterns on the ictal-interictal continuum (RPPIIC) per hour during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily duration of metabolic crisis</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of metabolic crisis (defined as Lactate Pyruvate ratio [LPR] &gt; 40 and lactate higher than 4 mmol/l) during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily duration of mitochondrial dysfunction</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of mitochondrial dysfunction (defined as LPR &gt; 40, Pyruvate &gt; 70 Î¼mol/l and partial brain tissue oxygenation [PbtO2] &gt; 20 mmHg) during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily duration of ischemia</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of ischemia (defined as PbtO2 &lt; 15 mmHg and cerebral perfusion pressure [CPP] &lt; 60 mmHg) during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily duration of elevated intracranial pressure (ICP)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Duration of elevated intracranial pressure (defined as ICP &gt; 22 mmHg) during continuous electrocorticography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropharmacology Cmax)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Cmax of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropharmacology (AUC)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>AUC of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropharmacology (t1/2)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>t1/2 of routinely used sedative drug concentrations in blood and brain (Esketamine, Midazolam and Propofol)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Absence or presence of hypoperfusion or ischemic infarctions in neuroimaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional patient outcome</measure>
    <time_frame>up to 6 months</time_frame>
    <description>modified Rankin Scale</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Traumatic Brain Injury</condition>
  <condition>Cortical Spreading Depolarization and Depression</condition>
  <condition>Seizures</condition>
  <condition>Ictal-Interictal Continuum</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microdialysis Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals between 18-80 years with poor grade aneurysmal SAH (World Federation&#xD;
        Neurosurgical Societies &gt;3), severe ICH (ICH Score &gt;3) or severe TBI (Glasgow Coma Scale&#xD;
        &lt;9).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between 18-80 years with poor grade aneurysmal SAH (World Federation&#xD;
             Neurosurgical Societies &gt;3), severe ICH (ICH Score &gt;3) or severe TBI (Glasgow Coma&#xD;
             Scale &lt; 9). The diagnosis of SAH, ICH and TBI will be established by computed&#xD;
             tomography (CT).&#xD;
&#xD;
          -  Individuals that are unlikely to regain consciousness within the following 48 hours.&#xD;
&#xD;
          -  Individuals that are expected to survive for the next 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals younger than 18 years old and older than 80 years.&#xD;
&#xD;
          -  Pregnant women (documented via positive Ã-HCG test).&#xD;
&#xD;
          -  Patients, who do not want to participate in the study. As the patient is not able to&#xD;
             consent prior to the study, information about the study details will be given to the&#xD;
             patient in case of clinical improvement. The patient information sheet will be handed&#xD;
             out.&#xD;
&#xD;
        Thereafter, the patient has the possibility to withdraw permission of study-participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Johannes Herta, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Herta, MD PhD</last_name>
    <phone>+43 (0)1 40400-25770</phone>
    <email>johannes.herta@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Koren, MD PhD</last_name>
    <phone>+43 (0)1 80110-2524</phone>
    <email>johannes.koren@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Herta, MD PhD</last_name>
      <phone>+43 (0)1 40400-25770</phone>
      <email>johannes.herta@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Johannes Koren, MD PhD</last_name>
      <phone>+43 (0)1 80110-2524</phone>
      <email>johannes.koren@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Johannes Herta</investigator_full_name>
    <investigator_title>Principle Investigator, Co-Head of the Neurosurgical ICU</investigator_title>
  </responsible_party>
  <keyword>Multimodal Neuromonitoring</keyword>
  <keyword>Electrocorticography</keyword>
  <keyword>Cerebral Microdialysis</keyword>
  <keyword>Neuropharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

